EZZ Life Science Holdings Ltd - Asset Resilience Ratio

Latest as of June 2025: 2.63%

EZZ Life Science Holdings Ltd (EZZ) has an Asset Resilience Ratio of 2.63% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of EZZ Life Science Holdings Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$891.50K

≈ $630.79K USD Cash + Short-term Investments

Total Assets

AU$33.96 Million

≈ $24.03 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2024)

This chart shows how EZZ Life Science Holdings Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is EZZ Life Science Holdings Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down EZZ Life Science Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read EZZ Life Science Holdings Ltd (EZZ) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$891.50K	2.63%
Total Liquid Assets	AU$891.50K	2.63%

Asset Resilience Insights

Limited Liquidity: EZZ Life Science Holdings Ltd maintains only 2.63% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

EZZ Life Science Holdings Ltd Industry Peers by Asset Resilience Ratio

Compare EZZ Life Science Holdings Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Celldex Therapeutics Inc NASDAQ:CLDX	Biotechnology	81.32%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Savara Inc NASDAQ:SVRA	Biotechnology	68.30%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%

Annual Asset Resilience Ratio for EZZ Life Science Holdings Ltd (2023–2024)

The table below shows the annual Asset Resilience Ratio data for EZZ Life Science Holdings Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.63%	AU$891.50K ≈ $630.79K	AU$33.96 Million ≈ $24.03 Million	+0.45pp
2023-12-31	2.18%	AU$556.49K ≈ $393.75K	AU$25.55 Million ≈ $18.08 Million	--

pp = percentage points

About EZZ Life Science Holdings Ltd

AU:EZZ Australia Biotechnology

Market Cap

$13.65 Million

AU$19.29 Million AUD

Market Cap Rank

#26355 Global

#1191 in Australia

Share Price

AU$0.41

Change (1 day)

-1.20%

52-Week Range

AU$0.37 - AU$3.32

All Time High

AU$4.93